Anagen effluvium is rapid hair loss that happens when something disrupts the hair’s growth phase (anagen). The most common cause is chemotherapy, but other medical exposures can do it too. Hair loss often begins within days to a few weeks after the trigger and can affect the scalp and sometimes eyebrows, eyelashes, and body hair.
Medical note: This article is for general education and does not provide personal medical advice. For the full roadmap, start here: Hair Loss (Complete Guide).
Quick navigation
- What it is (plain English)
- Why it happens
- Timeline & what to expect
- Anagen vs telogen effluvium
- How it’s diagnosed
- Care & practical tips
- When to see a doctor
- FAQ
- References
What is anagen effluvium?
Anagen effluvium is hair loss that happens because the hair shaft production is disrupted while hair is actively growing. Since a large percentage of scalp hairs are normally in anagen, the shedding can feel sudden and dramatic.
On our site, it belongs under: Non-Scarring Alopecia (Overview) and the main map: Types of Hair Loss.
Why it happens
The classic trigger is chemotherapy, which targets rapidly dividing cells (including hair matrix cells). Other medical exposures can sometimes cause similar effects, but chemotherapy is by far the most common context discussed.
Timeline & what to expect
- Days to 2–3 weeks: hair loss may begin (often earlier than telogen effluvium).
- Weeks 3–8: shedding can become heavy; scalp hair may thin diffusely.
- After the trigger ends: regrowth is often possible, but timing varies by medication and person.
- Regrowth phase: hair may initially come back finer or with texture changes; many people see improvement over months.
For a general expectations framework, also see: Prognosis & Expectations.
Anagen vs telogen effluvium (quick differences)
People often confuse anagen effluvium with telogen effluvium.
| Feature | Anagen effluvium | Telogen effluvium |
|---|---|---|
| Timing after trigger | Days to weeks | Usually 2–3 months later |
| Typical triggers | Chemotherapy (most common) | Illness, stress, surgery, postpartum, meds, deficiency |
| Pattern | Often sudden/diffuse | Diffuse shedding |
If you’re unsure whether you’re seeing shedding or breakage, start here: Shedding vs Breakage (Practical).
How it’s diagnosed
Diagnosis is usually based on the timeline (especially chemotherapy timing) and scalp exam. Your clinician may also review medications, cancer treatment plans, and other exposures.
Care & practical tips
- Be gentle: avoid harsh chemical treatments and minimize high-heat styling.
- Scalp comfort: mild shampoo, moisturize if dry/itchy, protect from sun/cold.
- Ask about prevention options: some cancer centers discuss scalp cooling for selected patients (not suitable for everyone).
- Manage expectations: regrowth often begins after the trigger ends, but timing varies.
For broader context, see: Treatment Overview.
When to see a doctor
- Severe scalp pain, burning, pustules, thick crusting
- Fever, feeling unwell, or signs of infection
- Concerns about scarring or shiny smooth areas
- Unclear cause or rapidly worsening hair loss outside an expected treatment timeline
Read: When to See a Doctor.
FAQ
Is anagen effluvium permanent?
Often it is not permanent, especially when caused by chemotherapy and the trigger ends. However, outcomes vary by treatment and individual factors.
How is it different from telogen effluvium?
Telogen effluvium typically starts a few months after a trigger and causes diffuse shedding. Anagen effluvium often begins sooner (days to weeks) and is strongly associated with chemotherapy.
Can I still have other hair-loss conditions at the same time?
Yes. It’s possible to overlap with other conditions such as androgenetic alopecia or telogen effluvium, depending on triggers and baseline risk.
References (trusted medical sources)
- DermNet: Anagen effluvium
- National Cancer Institute (NCI): Hair loss during cancer treatment
- American Cancer Society: Hair loss
- NCBI Bookshelf (StatPearls): Androgenetic Alopecia (baseline context)
Last updated: January 30, 2026.
